Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1

Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1

Patients co-infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are at high risk for liver disease progression. However, interferon-based treatments for HCV infection have significant toxicities, limiting treatment uptake.To assess the all-oral 3 direct-acting antiviral (3D)...

Whakaahuatanga katoa

I tiakina i:
Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua: Mark Sulkowski, Joseph J. Eron, David Wyles, Roger Trinh, Jay Lalezari, Chia Wang, Jihad Slim, Laveeza Bhatti, Joseph Gathe, Peter Ruane, Richard Elion, Fritz Bredeek, Robert T. Brennan, Gary Blick, Amit Khatri, Krystal Gibbons, Yiran Hu, Linda Fredrick, Gretja Schnell, Edward Tam, Rakesh Tripathi, Barbara Da Silva‐Tillmann, Barbara McGovern, Andrew Campbell, Thomas Podsadecki
Hōputu: Artigo
Reo:Ingarihi
I whakaputaina: 2015
Urunga tuihono:https://doi.org/10.1001/jama.2015.1328
https://jamanetwork.com/journals/jama/articlepdf/2173265/joi150019.pdf
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ipurangi

https://doi.org/10.1001/jama.2015.1328
https://jamanetwork.com/journals/jama/articlepdf/2173265/joi150019.pdf

Ngā tūemi rite